- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04754854
Minskning av återcirkulation av blod i veno-venös ECMO
Minskning av blodåtercirkulation i veno-venös ECMO genom ultraljudsutspädningsmätningar (ECMO Circulation Study)
Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.
A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.
ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.
Studieöversikt
Status
Detaljerad beskrivning
Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
State of Berlin
-
Berlin, State of Berlin, Tyskland, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Inclusion Criteria:
- patients aged 18 years or older
- ARDS
- veno-venous ECMO
Exclusion Criteria:
- age < 18 years
- hemodynamic instability during measurement of recirculation
- pregnancy
- inability to obtain patient's consent or consent of legal guardian
Beskrivning
Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Successful ECMO blood flow reduction
Tidsram: Once within the first week after initiation of ECMO therapy
|
Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction |
Once within the first week after initiation of ECMO therapy
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Recirculation fraction
Tidsram: Once within the first week after initiation of ECMO therapy
|
Fraction of blood recirculating through the ECMO circuit |
Once within the first week after initiation of ECMO therapy
|
|
Arterial blood oxygen content
Tidsram: Once within the first week after initiation of ECMO therapy
|
Arterial blood oxygen content before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal blood Flow
Tidsram: Once within the first week after initiation of ECMO therapy
|
ECMO Blood Flow before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal gas flow
Tidsram: Once within the first week after initiation of ECMO therapy
|
ECMO Sweep Gas flow |
Once within the first week after initiation of ECMO therapy
|
|
Length of ECMO therapy
Tidsram: Daily until the end of ECMO therapy (approximately 14 days)
|
Days on ECMO |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Cannula position and distance
Tidsram: Once within the first week after initiation of ECMO therapy
|
The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans) |
Once within the first week after initiation of ECMO therapy
|
|
Right heart dysfunction
Tidsram: Once within the first week after initiation of ECMO therapy
|
Existing echocardiography will be evaluated for possible right heart dysfunction |
Once within the first week after initiation of ECMO therapy
|
|
Length of mechanical ventilation
Tidsram: Entire duration of the ICU stay (approximately 28 days)
|
Length of mechanical ventilation |
Entire duration of the ICU stay (approximately 28 days)
|
|
Complications of ECMO therapy
Tidsram: Length of ECMO therapy (approximately 14 days)
|
Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis |
Length of ECMO therapy (approximately 14 days)
|
|
ICU mortality
Tidsram: Entire duration of the ICU stay (approximately 28 days)
|
ICU mortality |
Entire duration of the ICU stay (approximately 28 days)
|
|
ICU length of stay
Tidsram: Entire duration of the ICU stay (approximately 28 days)
|
ICU length of stay |
Entire duration of the ICU stay (approximately 28 days)
|
|
Incidence of ICU-acquired organ dysfunctions and complications
Tidsram: Entire duration of the ICU stay (approximately 28 days)
|
Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections |
Entire duration of the ICU stay (approximately 28 days)
|
|
ECMO blood flow over time
Tidsram: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO blood and sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
ECMO sweep gas flow over time
Tidsram: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Mobility at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)
|
Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently) |
Discharge from the ICU (approximately 28 days)
|
|
Weaning level at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)
|
Level of weaning reached at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Status of mechanical ventilation at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)
|
Status of mechanical ventilation at ICU discharge including all relevant settings and parameters |
Discharge from the ICU (approximately 28 days)
|
|
Level of organ dysfunction at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)
|
Sepsis-related Organ Failure Assessment Score at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of consciousness at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)
|
Glasgow Coma Scale at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of disease severity
Tidsram: Discharge from the ICU (approximately 28 days)
|
Acute Physiology And Chronic Health Evaluation at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Hospital acquired infections related to ECMO therapy
Tidsram: Entire duration of ECMO therapy
|
Infection/colonisation of the ECMO circuit |
Entire duration of ECMO therapy
|
|
Bleeding and thrombembolic complications of ECMO therapy
Tidsram: Entire duration of ECMO therapy
|
Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit |
Entire duration of ECMO therapy
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Martin Russ, Dr. med., Charite University Hospital Berlin
- Huvudutredare: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
- Huvudutredare: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
- Huvudutredare: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- EA115620
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .